In a report released today, Boobalan Pachaiyappan from H.C. Wainwright reiterated a Buy rating on Ensysce Biosciences (ENSC – Research Report), with a price target of $7.00. The company’s shares closed last Friday at $1.52.
Pachaiyappan covers the Healthcare sector, focusing on stocks such as Brainsway, Galera Therapeutics, and Gain Therapeutics. According to TipRanks, Pachaiyappan has an average return of -1.4% and a 44.00% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ensysce Biosciences with a $7.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $65.52 and a one-year low of $1.49. Currently, Ensysce Biosciences has an average volume of 254.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ensysce Biosciences (ENSC) Company Description:
Leisure Acquisition Corp. operates as blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on the location-based leisure sector and leisure-related businesses. Leisure Acquisition was founded on September 11, 2017 and is headquartered in New York, NY.
Read More on ENSC:
